European Commission Targets Teva Over Alleged Copaxone Antitrust Breach

Teva Prepared To Use All Legal And Procedural Rights Available

A European Commission investigation into Teva’s conduct over its Copaxone multiple sclerosis drug has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.

EU Brussels
Teva faced unannounced inspections by the European Commission • Source: Shutterstock

Teva is prepared to leave no stone unturned in defending itself following the European Commission’s preliminary finding that the Israeli firm breached EU antitrust rules over Copaxone (glatiramer acetate), including by “artificially expanding” the multiple sclerosis treatment’s patent life to delay generic competition.

The commission also alleged that Teva had “systematically spread misleading information about a competing product with a view to hinder...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet